Loading…
ENSC
Ensysce Biosciences, Inc.
NASDAQ· Healthcare· Biotechnology· CUSIP 293602504
$0.40+0.23%Price as of Aug 29, 18:45 UTC · updated once a day, after the close
Key metrics
- Market cap
- $7.78M
- P/E
- —
- Forward P/E
- —
- P/B
- —
- Dividend yield
- —
- Payout
- —
- EPS
- -$2.54
- ROE
- -1295.09%
- Profit margin
- -280.48%
- Revenue growth
- -15.10%
- Beta
- —
- 52-week high
- $2.75
- 52-week low
- $0.23
History
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Investors holding this
Major managers that reported this stock in their latest 13F.
Price over time
▼ -100.0% over 5Y.
today you would have $0.04▼ -100.0%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
Indicators, year by year
The last 4 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Year-end price | $0.92 | $8.14 | $15.90 | $135.00 | |
| P/B | — | 1.3x | 3.0x | — | — |
| EPS | -$3.98 | -$11.45 | -$70.40 | -$2,091.60 | |
| ROE | — | -316.63% | -215.37% | — | — |
Median, not average: a single year of near-zero profit produces a P/E of 400 and would drag an average on its own. P/E years above 200x are left out, the same cut the fair price uses — so this median matches the “its own history” method below. Price and EPS have no median: they are series that grow.
Others in the same sector
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| ITOCiTonic Holdings Ltd | $0.32 | — | 0.9x | — | -71.25% | $7.83M |
| SKYESkye Bioscience, Inc. | $1.78 | — | — | — | -233.87% | $7.86M |
| AIMAIM ImmunoTech Inc. | $0.26 | — | 1.0x | — | -2382.30% | $7.87M |
| TRIBTrinity Biotech PLC | $9.68 |
About the company
Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, develops prescription drugs for severe pain relief in opioid misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection (TAAP) platform, designed to release clinically effective drugs only when exposed to specific physiological conditions; and Multi-Pill Abuse Resistance (MPAR) platform, an over-dose protection opioid prodrug technology. The company's lead product candidate is PF614, a TAAP oxycodone prodrug candidate for the treatment of severe or chronic pain; and PF614-MPAR, a combination product of PF614 and nafamostat for overdose protection. It is also developing PF8001 and PF8026 are extended and immediate-release prodrugs of amphetamine for attention deficit hyperactivity disorder; and PF9001 to treat opioid use disorder. Ensysce Biosciences, Inc. was founded in 2003 and is based in La Jolla, California.
- 8
- La Jolla, United States
Company description provided by Yahoo Finance.